Member Info for gadgie

don't know if still valid but :
The optofluidic chips at the heart of the system are covered in a protein – Aptamer, Affirmer – that is specifically developed to bind the Spike Protein of SARS CV 2 with 100% specificity. Aptamers and Affirmers are already being developed for E. coli, Legionella, Cryptosporidium, Norovirus and PMMoV.

The Microtox PD range also effectively detects chemicals and other substances at lower molecule levels. With 100% specificity, it can zero in on substances that were not measurable or may be newly introduced. Medicines, pesticides, personal care, hormones, plasticizers, detergents, food additives, surfactant product compounds end up in wastewater systems, potentially making their way into water sources.

https://www.modernwater.com/2021/10/06/monitoring-wastewater-to-provide-faster-real-time-detection-of-covid-19-and-other-pathogens/

Tight Ship can't find anything and trust me I'm looking ..... GMCC top researcher over to you .....

Again Excellent thank you gmcc

Hi Staying put :)

https://www.fiercebiotech.com/biotech/late-car-t-game-astrazeneca-quietly-working-its-own-shelf-options

Avacta considered as a Major player in this Market :
https://crestiad-com.translate.goog/uncategorized/435356/????????-t-car-t-????-????????/?_x_tr_sl=zh-CN&_x_tr_tl=en&_x_tr_hl=en&_x_tr_pto=sc

Thursday is also shaping up to be a busy trading day for biotech. Amgen (AMGN) announced a $4 billion all-cash acquisition of ChemoCentryx (CCXI), which recently received Food and Drug Administration approval for a drug Tavneos that treats an autoimmune condition called ANCA-associated vasculitis. ChemoCentryx shares were up 108.4% premarket, while Amgen shares were flat.

Gilead also announced a deal on Thursday, snapping up a private U.K.-based biotech called MiroBio for $405 million in cash. Gilead shares were down 0.3% in premarket trading.

again well done .... must admit Avacta are very tight on the info front no leaks :)

latest round stonebridge invested 1.8 million into affyxell :
https://www-thebell-co-kr.translate.goog/free/Content/ArticleView.asp?key=202207141515200760106768&svccode=03&_x_tr_sch=http&_x_tr_sl=ko&_x_tr_tl=en&_x_tr_hl=en&_x_tr_pto=sc

If it wasn't working we would be aware and the trial would have stopped / paused .... I would imagine Avacta are under immense pressure to release Data .... Millions invested to date ...
Point Biopharma (canseek ) waiting data
Daewoong multiple targets
LG Multiple Targets and milestone payments made £6 Million to date ?
Affyxell
Never in all my years of investing have a seen such a dead cert !!! all IMHO ....DYOR

even at the standard dose .... targeted warhead in the tumour microenvironment with no / little side effects it's a success

Never IMHO has it been so true ....
Wouldn't want to be out overnight ...
Rockets firing Up ...
News at anytime and Major Inflection point / re rate certainly won't be able to buy under £2 on RN's day all IMHO ...
So many shots on goal

Nice to have Daewoong on board ........

gmcc ..... you cannot be beaten top research .... Thankyou

Hi gmcc thank you ..... surely they have something to say .... for sure they won't be going on the basis of a suspended LFT ? .... If they do have anything I'm sure we will hear 07:00 Buddy

Surely we have something to put out ?

https://events.jspargo.com/aacc22/Public/eBooth.aspx?IndexInList=0&FromPage=Exhibitors.aspx&ParentBoothID=&ListByBooth=true&BoothID=834706

agreed ... love the statement ..... releases active drug only in the tumour .......

https://jobs.chemistryworld.com/job/36953/senior-protein-scientist/
This targeted chemotherapy platform releases active drug only in the tumour, thereby limiting systemic exposure of potentially toxic anti-cancer treatments.

thank you ... too old for twitter :)

Anyone have updated version don't see Blackrock ?
https://www.marketscreener.com/quote/stock/AVACTA-GROUP-PLC-4004322/company/

Hargreaves Lansdown Stockbrokers Ltd. 46,472,000 18.2%
Jarvis Investment Management Ltd. 18,073,000 7.08%
Hargreaves Lansdown Asset Management Ltd. 15,629,000 6.12%
Premier Fund Managers Ltd. 11,609,794 4.55%
Baillie Gifford & Co. 11,515,758 4.51%
Lombard Odier Asset Management (Europe) Ltd. 9,979,863 3.91%
J.O. Hambro Capital Management Ltd. 8,625,000 3.38%
Carlton International Holdings Ltd. 8,400,000 3.29%
Conifer Management LLC 7,575,786 2.97%
Unicorn Asset Management Ltd. 6,000,000 2.35%

An Apicell Therapeutics official said, “Before supporting the project, we conducted a sufficient pre-test to see if the 'serum-free chemical composition medium' developed and commercialized by Excel Therapeutics can be applied to transgenic stem cells, and it is possible to create sufficiently meaningful results. I am confident that there is,” he said.